Immunotherapy plus chemotherapy with or without an antihistamine for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding an antihistamine (a common allergy medicine) to the usual combination of an immunotherapy drug (toripalimab) and chemotherapy, given before and after surgery, helps treat stage II or III non-small cell lung cancer better than without it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 75 years.
- Diagnosed with stage II or III non-small cell lung cancer (a common type) that can be removed with surgery.
- If your cancer is a certain subtype (adenocarcinoma), you must have tested negative for EGFR and ALK gene mutations.
- You must not have had any prior chemotherapy, immunotherapy, or radiation for your lung cancer (except for certain exceptions).
- You should be in good overall health with adequate liver, kidney, blood, and thyroid function as shown by lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests a combination of an immunotherapy drug (Rilpufan α) with chemotherapy given before surgery for early-stage (stage II-III) non-small cell lung cancer. The goal is to shrink the tumor to make surgery more effective and potentially improve long-term outcomes.
This trial tests a new combination for advanced lung cancer: an immunotherapy drug (tislelizumab) plus standard chemotherapy, and adds a common allergy medicine (diphenhydramine) to see if it improves outcomes. It's for people who haven't had prior systemic treatment for their lung cancer and are generally healthy.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.